Recent monetary policy meetings at various central banks around have led to massive downturns in the US Dollar. The latest example of this was seen with this week's interest rate decision from the Bank of Japan (BoJ), which was a relative disappointment for traders bearish on the Japanese Yen. The currency is now seeing gains against all of its 16 most commonly traded counterparts, as expectations that the central bank would enact measures to calm volatility in Japanese bonds were proven incorrect. The main take-away from the central bank meeting was that the BoJ sees no immediate need to extend the maturities in private bank loans, and the knee-jerk reaction in the markets was to reverse short Yen positions, sending the USD/JPY to its lowest levels since April.
BoJ Policy MeetingIn ETFs, this translates to substantially bearish moves in PowerShares DB US Dollar Index Bullish (UUP) and highly bullish moves in theCurrencyShares Japanese Yen Trust (FXY). The BoJ left policy unchanged, with no stated plans to alter the 60 trillion Yen ($611 billion) in annual injections to the country's monetary base. Most analysts were expecting the BoJ would approve loan operations that extend to two years (or longer), and the results put renewed focus on the 10-year Japanese treasury note. Since the BoJ announced its historic stimulus plan in April, the 10-year note has risen from its all-time lows at 0.315% to highs of 1%. The main ideological thrust of the BoJ must be kept in perspective, however, as there is still clear long-term concern for the prospects of the country's export companies and pronounced efforts in place to bring consumer inflation levels back toward normal ranges.
Best Quality Companies To Buy For 2015: Value Line Inc (VALU)
Value Line, Inc., incorporated on October 29, 1982, is engaged in producing investment periodicals and related publications and making available copyright data, including certain Ranking System and other information, to third parties under written agreements for use in third-party managed and marketed investment products. The Company operates in two segments: investment periodicals and related publications. During the fiscal year ended March 31, 2013 (fiscal 2013), the Company�� Wholly-owned operating subsidiaries include Value Line Publishing LLC, Vanderbilt Advertising Agency, Compupower Corporation (CPWR) and Value Line Distribution Center (VLDC). The Company markets under brands including Value Line, the Value Line Logo, The Value Line Investment Survey and The Most Trusted Name in Investment Research.
Investment Related Periodicals and Publications
The investment periodicals and related publications offered by Value Line Publishing LLC (VLP) covers a spectrum of investments, including stocks, mutual funds, options and convertible securities. The services generally fall into four categories include Comprehensive reference periodical publications; Targeted, niche periodical newsletters, and Current and historical financial databases. The services (The Value Line Investment Survey, The Value Line Investment Survey - Small and Mid-Cap, The Value Line 600, and The Value Line Fund Advisor Plus) provide both statistical and text coverage of a number of investment securities, with a focus placed on Value Line's research, analysis and statistical ranks. The Value Line Investment Survey is the Company's premier service, published each week and covering approximately 1,700 stocks.
The newsletters (The Value Line Special Situations Service, The Value Line Fund Advisor, The Value Line Convertibles Survey and The Value Line Options Survey) provide information on securities. The Company offers online versions of its products at the Company's Website, www.valueline.com. T! he Value Line Investment Survey is an investment periodical research product providing both timely articles on economic, financial and investment matters and analysis and ranks for equity securities. The Value Line Investment Survey is an investment periodical research product providing both timely articles on economic, financial and investment matters and analysis and ranks for equity securities. The Value Line Investment Survey - Small and Mid-Cap is an investment research product that provides short descriptions of and data for approximately 1,800 small and medium-capitalization stocks.
Value Line Investment Analyzer is a menu-driven software program with filtering, ranking, reporting and graphing capabilities utilizing over 350 data fields for range of industries and indices and for the approximately 1,700 stocks covered in VLP's publication, The Value Line Investment Survey. Value Line Investment Analyzer allows subscribers to apply more than 60 charting and graphing variables for comparative research. Value Line Mutual Fund Survey for Windows is a monthly CD-ROM or Internet product with weekly Internet updates. The program features powerful sorting and filtering analysis tools. It includes features, such as style attribution analysis, a portfolio stress tester, portfolio rebalancing, correlation of fund returns and hypothetical assets. For the Company's institutional customers, Value Line offers both current and historical data for equities, mutual funds, exchange traded funds (ETFs), and convertibles.
Value Line's Fundamental DataFile I contains fundamental data (both current and historical) on approximately 6,400 publicly traded companies that follow United States generally accepted accounting principles (GAAP). Estimates and Projections DataFile offering contains the estimates from Value Line analysts on approximately 1,700 companies. Data includes earnings, sales, cash flow, book value, margin, and other popular fields. Projections are for the future one year, three ! year and ! five year periods. The Value Line Mutual Fund DataFile, covers more than 20,000 mutual funds with up to 20 years of historical data with more than 200 data fields. The Mutual Fund DataFile provides monthly pricing, basic fund information, weekly performance data, sector weights, and many other popular mutual fund data fields. The Value Line Research Center provides on-line access to select Company investment research products covering stocks, mutual funds, options and convertible securities, as well as special situation stocks.
Copyright Data Fees Programs
The Company has copyright data, which include certain ranking system information and other information used in third party products, such as unit investment trusts, variable annuities, managed accounts and exchange traded funds, which it distributes under copyright data agreements. The Company�� primary copyright data products have been structured as unit investment trusts, ETFs, annuity products and other types of managed products.
Investment Management Services
The Company through its wholly-owned subsidiary ESI, was the distributor for the Value Line Funds. State Street Bank is the custodian of the assets of the Value Line Funds and provides them with fund accounting and administrative services. Shareholder services for the Value Line Funds are provided by Boston Financial Data Services, an affiliate of State Street Bank.
Advisors' Opinion:- [By Geoff Gannon] be cheap enough. It was an issue of Warren Buffett being confident enough to invest in IBM.
By the way, let�� look at IBM�� past record:
10-Year Average Return on Assets: 10.3%
10-Year Annual Sales Growth: 2.8%
10-Year Annual Asset Growth: 1.9%
As you can see, IBM isn�� much of a growth company. But that doesn�� mean the shares can�� be growth shares. IBM has improved margins and bought back stock. That has led to a 20% annual increase in earnings per share compared to just a 3% annual increase in total revenue.
So can we answer the question of why Warren Buffett is interested in companies like IBM and Norfolk Southern (NSC) rather than Hewlett-Packard and Value Line?
Well, Value Line is obviously too small an investment for Buffett. But we��e using it as a stand in for all the publishers Buffett once loved but now shuns.
Buffett is a return on investment investor. He isn�� exactly a growth investor or a value investor ��if by growth we mean total revenue growth and if by value we mean the company�� value as of today.
Buffett wants to compound his money at the fastest rate possible. So he looks at how much of the company�� sales, assets, etc. he is getting. Basically, he looks at a price ratio. And then he looks into the company�� return on its own sales, assets, etc. When you take those two numbers together you get something very close to a rate of return.
The last part you need to consider is the change in assets versus the change in sales (and earnings). Does the company need to grow assets faster than earnings?
Or ��like See�� Candy ��can it grow sales a little faster than assets?
Let�� take a look at Norfolk Southern as a good example of the kind of railroad Buffett would own ��if he didn�� own all of Burlington Northern.
Norfolk Southern
10-Year Average Return on Assets: 4.9%
10-Year Annual Sales Growth: 6.0%
10-Year Annual Asset Gr
Top Japanese Stocks To Watch For 2014: Silicon Laboratories Inc.(SLAB)
Silicon Laboratories Inc., a fabless semiconductor company, designs, develops, and markets analog-intensive and mixed-signal integrated circuits (ICs). The company offers broad-based products, which include microcontrollers, clocks and oscillators, wireless transceivers, digital isolators and related products, and human interface sensors and controllers; broadcast products comprising radio receivers and transmitters, and video tuners and demodulators; and access products consisting of embedded modems, subscriber line interface circuits, Voice over IP (VoIP) products, and power over Ethernet devices, as well as DSL analog front end ICs and IRDA devices. It provides ICs for use in various electronic applications, such as portable devices, AM/FM radios, and other consumer electronics, as well as networking, test and measurement, industrial monitoring and control, and customer premises equipment. The company markets its products through direct sales force, and through a networ k of independent sales representatives and distributors in the United States, Taiwan, China, South Korea, Japan, and internationally. Silicon Laboratories Inc. was founded in 1996 and is headquartered in Austin, Texas.
Advisors' Opinion:- [By Garrett Cook]
In trading on Friday, technology shares were relative laggards, down on the day by about 0.80 percent. Top decliners in the sector included Silicon Laboratories (NASDAQ: SLAB), down 13.7 percent, and Informatica (NASDAQ: INFA), off 13.4 percent.
- [By Rich Smith]
Austin, Texas-based Silicon Laboratories (NASDAQ: SLAB ) , which chose a new chief financial officer last month, has now found him a bit of extra work to do.
- [By MONEYMORNING.COM]
XSD holds such big-cap names as Texas Instruments Inc. (Nasdaq: TXN) and Intel Corp. (Nasdaq: INTC). It also owns Atmel Corp. (Nasdaq: ATML), which has a market cap of less than $4 billion, and Silicon Laboratories Inc. (Nasdaq: SLAB), with a market cap of $2 billion.
- [By Garrett Cook]
In trading on Friday, technology shares were relative laggards, down on the day by about 0.80 percent. Top decliners in the sector included Silicon Laboratories (NASDAQ: SLAB), down 15.32 percent, and Informatica (NASDAQ: INFA), off 11.91 percent.
Top Japanese Stocks To Watch For 2014: Acceleron Pharma Inc (XLRN)
Acceleron Pharma Inc., incorporated on June 13, 2003, is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of protein therapeutics for cancer and rare diseases. The Company�� research focuses on the biology of the Transforming Growth Factor-Beta (TGF-b) protein superfamily, a large and diverse group of molecules that are key regulators in the growth and repair of tissues throughout the human body. By coupling its discovery and development expertise, including its knowledge of the TGF-b superfamily, with its internal protein engineering and manufacturing capabilities, it has built a productive research and development platform that has generated clinical and preclinical protein therapeutic candidates with mechanisms of action.
The Company focuses on discovering and developing protein therapeutics that target a group of approximately 30 secreted proteins, or ligands, that are collectively referred to as the TGF-b superfamily. These ligands bind to subsets of 12 different receptors on the surface of cells, triggering intra-cellular changes in gene expression that guide cell growth and differentiation. The TGF-b superfamily ligands and their receptors represent an under-explored and diverse set of drug targets with the potential to yield therapeutics that modulate the growth and repair of diseased cells and tissues.
The Company has three internally discovered protein therapeutic candidates that are being studied in 12 ongoing Phase 2 clinical trials, focused on cancer and rare diseases. The Company�� two advanced protein therapeutic candidates, sotatercept and ACE-536, promote red blood cell production through a novel mechanism. Together with its collaboration partner, Celgene Corporation, the Company is developing sotatercept and ACE-536 to treat anemia and associated complications in patients with b-thalassemia and myelodysplastic syndromes (MDS). These red blood cell disorders are generally unresponsive to approved dru! gs. The Company�� third clinical stage protein therapeutic candidate, dalantercept, is designed to inhibit blood vessel formation through a mechanism that is distinct from, and potentially synergistic with, the dominant class of cancer drugs that inhibit blood vessel formation, the vascular endothelial growth factor (VEGF) pathway inhibitors. The Company is developing dalantercept primarily for use in combination with these products to produce better outcomes for cancer patients.
The Company and Celgene have conducted six human clinical trials with sotatercept in over 160 healthy volunteers and cancer patients. The Company has conducted one clinical trial with ACE-536 in healthy volunteers. In these studies, both sotatercept and ACE-536 caused a dose-dependent increase in the number of red blood cells. Based on these results, the Company and Celgene have initiated Phase II clinical trials with each of these protein therapeutic candidates in b-thalassemia and MDS. In the ongoing trial of sotatercept in patients with b-thalassemia, the Company has observed encouraging, dose-dependent increases in hemoglobin in a subset of patients at the two lowest dose levels.
Sotatercept is a soluble receptor fusion protein consisting of the extracellular domain of the activin receptor type IIA (ActRIIA) linked to the Fc domain of human IgG1. Sotatercept acts as a protein trap for TGF-b superfamily ligands that signal through the ActRIIA receptor. Sotatercept has increased red blood cells in multiple clinical trials. ACE-536 is a soluble receptor fusion protein consisting of a modified extracellular domain of the activin receptor type IIB (ActRIIB) linked to the Fc domain of human IgG1.
Advisors' Opinion:- [By Ben Levisohn]
3. We see 23+ partnered pipeline assets and are most positive on Phase I/II MOR202 anti-CD38 for myeloma with data in 2015, and others such as Acceleron Pharma (XLRN), Agios Pharmaceuticals (AGIO), Epizyme (EPZM), Concert Pharmaceuticals (CNCE) (just started Phase I for next-gen Revlimid).
- [By Monica Gerson]
Breaking news
Acceleron Pharma (NASDAQ: XLRN) today announced that it has commenced an underwritten public offering of $100 million of its common stock. To read the full news, click here. XenoPort (NASDAQ: XNPT) announced today that it intends to offer and sell 10,000,000 shares of its common stock, subject to market and other conditions, in an underwritten public offering. To read the full news, click here. Affymetrix (NASDAQ: AFFX) today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its CytoScan庐 Dx Assay. To read the full news, click here. Verizon Communications (NYSE: VZ) and Intel (NASDAQ: INTC) today announced an agreement for Verizon to purchase from Intel the assets of Intel Media, a business division dedicated to the development of Cloud TV products and services. To read the full news, click here.Posted-In: Evercore Partners US Stock FuturesNews Eurozone Futures Global Pre-Market Outlook Markets
- [By Jake L'Ecuyer]
Shares of Acceleron Pharma (NASDAQ: XLRN) got a boost, shooting up 16.74 percent to $39.54 after Form 8-K for Acceleron Pharma showed that Celgene (NASDAQ: CELG) will buy 1.1 million shares for $47.15 million.
- [By Jake L'Ecuyer]
Shares of Acceleron Pharma (NASDAQ: XLRN) got a boost, shooting up 16.39 percent to $39.42 after Form 8-K for Acceleron Pharma showed that Celgene (NASDAQ: CELG) will buy 1.1 million shares for $47.15 million.
Top Japanese Stocks To Watch For 2014: Vanda Pharmaceuticals Inc.(VNDA)
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system disorders. Its lead product includes Fanapt for the acute treatment of schizophrenia in adults. The company is also developing Tasimelteon, an orphan medicinal product for the treatment of sleep and mood disorders, including non-24 hour sleep/wake disorder in blind individuals without light perception. It also intends to initiate a Phase IIb/III clinical trial of tasimelteon in patients with major depressive disorder; and conduct additional clinical trials to support the use of tasimelteon as a circadian regulator. The company was incorporated in 2002 and is headquartered in Rockville, Maryland.
Advisors' Opinion:- [By Ben Levisohn]
It was the night before the ECB–and two before US payrolls–and all through the market nothing was stirring, not even…Alright. Some things were stirring, like the shares of Protective Life (PL), Travelers Companies (TRV), Under Armour (UA), Broadcom (BRCM) and Vanda Pharmaceuticals (VNDA).
- [By MONEYMORNING.COM]
The FDA Peripheral and Central Nervous System Drugs Advisory Committee (AdCom) met last November to review Vanda Pharmaceuticals Inc.'s (Nasdaq: VNDA) New Drug Application (NDA) for tasimelteon, an experimental drug for the treatment of a serious condition among blind people that radically affects their sleeping patterns: non-24-hour disorder. The panel voted overwhelmingly in favor of tasimelteon. Vanda's stock share price rocketed upward 115%.
In January 2014, FDA's Cardiovascular and Renal Drugs Advisory Committee voted 16 to 1 in favor of approval for Chelsea Therapeutics International Ltd.'s (Nasdaq: CHTP) pipeline drug Northera (droxidopa), designed to prevent dizziness and fainting among patients with neurodegenerative diseases. Chelsea's share price immediately soared 150%. - [By John Udovich]
Small cap biopharmaceutical stock�Vanda Pharmaceuticals Inc (NASDAQ: VNDA) surged 14.02% after announcing a settlement agreement with Novartis AG (NYSE: NVS) related to ongoing license arbitration proceedings for Fanapt, a schizophrenia treatment drug���meaning its worth taking a closer look at the stock along with large caps Johnson & Johnson (NYSE: JNJ) and Bristol-Myers Squibb Co (NYSE: BMY) which also have important schizophrenia drugs in their portfolios.
- [By Nathalie Tadena]
Among the companies with shares expected to actively trade in Friday’s session are Vanda Pharmaceuticals Inc.(VNDA), Kimberly-Clark(KMB) and Cell Therapeutics(CTIC).
Top Japanese Stocks To Watch For 2014: Societe B I C SA (BB)
Societe B I C SA is a France-based company specialized in the manufacturing of stationery products, lighters and shavers. The Company's portfolio of trademark brands belong: BIC, Sheaffer, BIC Kids, Wite-out, Pimaco and Tipp-ex, among others. Channels of distribution include stationery stores, office product companies, mass-merchandisers, convenience stores, wholesalers and cash and carry outlets. It operates worldwide through numerous subsidiaries in Europe, Middle East, Africa Northern America, Latin America, Asia and Oceania. In addition, the Company provides, via BIC Graphic and Norwood PP, advertising and promotional products for marketing purposes to companies around the world, as well as a range of windsurfing boards, kayaks and others, under the brand BIC Sport. Advisors' Opinion:- [By Eric Lam]
Bankers Petroleum Ltd. (BNK) climbed a fourth day to the highest level in a year. Endeavour Silver Corp. rose 2.1 percent as silver prices rallied for a seventh straight day, the longest streak since January. BlackBerry Ltd. (BB) fell 3.9 percent.
- [By Eric Lam]
Canadian stocks fell for a second day as BlackBerry (BB) Ltd. plunged the most in three months and gold producers slumped after a Federal Reserve policy maker said a small tapering of bond buying is possible next month.
- [By Eric Lam]
BlackBerry Ltd. (BB) dropped 2.7 percent, snapping three days of gains. Bombardier Inc. lost 1 percent after rallying the most in four months yesterday. Torex Gold Resources Inc. and B2Gold Corp. added at least 4.8 percent as the price of gold climbed. Air Canada, the nation�� largest airline, jumped 3.1 percent after announcing it will refinance its long-term debt at a lower cost. Suncor Energy Inc. rose 1.2 percent as crude rallied to a two-year high.
- [By Eric Lam]
Rogers Communications Inc. (RCI/B) and Telus Corp. advanced at least 5.5 percent as telephone stocks surged the most in more than four years. Teck Resources Ltd. and First Quantum Minerals Ltd. added more than 1.7 percent as the price of copper climbed on signs of improving growth in China and the U.S. BlackBerry Ltd. (BB), which is weighing a sale, increased 1 percent after Microsoft Corp. agreed to acquire Nokia Oyj�� handset business.
Top Japanese Stocks To Watch For 2014: Alkaline Water Company Inc (WTER)
The Alkaline Water Company Inc., formerly Global Lines Inc, incorporated on June 6, 2011, is a developer of electrolysis beverage process, packaged and branded as Alkaline84. Alkaline84 is the Company's flagship product designed to encourage daily consumption of Alkaline Water through a consumer oriented bulk delivery system. The Company is engaged in the development of a national retail bulk distribution network delivering Electrochemically Activated Water (ECA) to consumers everywhere. The Company is focused on the business of distributing and marketing the retail sale of its packaged Alkaline84 branded beverage products.
Alkaline84 is available in two sizes: three liters and one gallon. Alkaline84 is a pH balanced bottled alkaline drinking water enhanced with 84 trace minerals and electrolytes. Alkaline84 is available for consumer sales at a number of major retail locations across the southwestern United States.
Advisors' Opinion:- [By Bryan Murphy]
PepsiCo, Inc. (NYSE:PEP), consider your dominance in the bottled water arena - via Aquafina - under a serious attack. And for The Coca-Cola Company (NYSE:KO), well, your Dasani brand's #2 position in the market share race isn't as secure as you'd like it to be either. There's a new name in town you need to watch out for - Alkaline Water Company Inc. (OTCBB:WTER). This young company is hungry... well, thirsty, and with its impressive product already making a big splash in the few markets its been introduced to, WTER is not only positioned to make a dent in the bottled water revenue being generated by the likes of KO and PEP, this little company may be serving up some solid gains for its investors as well.
No comments:
Post a Comment